Lower-cost Praluent dose may be Sanofi's weapon against Amgen's rival PCSK9 med

Payers have promised a fight over the price of PCSK9 drugs, a new class of cholesterol fighters expected to be a pricey proposition. Drugmakers in the field--including frontrunners Amgen ($AMGN) and Sanofi ($SNY)--have been preparing for that fight. And Sanofi appears to be readying a low-dose, lower-cost option for its Praluent drug in a bid to undercut Amgen's rival Repatha. More from FiercePharmaMarketing